Aptevo shares are trading lower after the company released duration of remission data from Phase 1b expansion trial of APVO436 for Acute myelogenous leukemia.
Portfolio Pulse from Benzinga Newsdesk
Aptevo Therapeutics has released duration of remission data from its Phase 1b expansion trial of APVO436 for Acute myelogenous leukemia, causing its shares to trade lower.
July 18, 2023 | 2:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Aptevo's stock is trading lower following the release of remission data from its Phase 1b trial of APVO436 for Acute myelogenous leukemia.
The release of the remission data from the Phase 1b trial of APVO436 is a significant event for Aptevo. The negative market reaction suggests that the results may not have met investor expectations, leading to a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100